Gland Pharma Ltd. (GLAND): Gland Pharma Share Price rises 2.26% to Rs 2,929.90; market cap at Rs 47,318.21 crore

Gland Pharma Share Price is trading at Rs 2,929.90, up 2.26% from the previous close, with a market capitalisation of Rs 47,318.21 crore. The move makes Gland Pharma Share Price Today one of the notable healthcare moves in the Indian stock market, even though the latest Univest data confirms the price event without establishing a company-specific catalyst. Gland Pharma stock news is therefore centered on verified price action, valuation and sector context rather than a fresh trigger. For investors tracking Gland Pharma Share Price Live, the immediate focus is on how the stock is positioned versus its healthcare peers, what the ratio profile says about current pricing and whether the move is being supported by broader market interest in pharmaceutical names. Univest data also helps place the latest share price rise into a cleaner research frame.

Gland Pharma Share Price Today: Price Action Analysis

Gland Pharma Ltd. (GLAND) rose to Rs 2,929.9 from the previous close of Rs 2,865.15, a move of Rs 64.75 or 2.26%. The stock opened at Rs 2,905.1, reached a high of Rs 2,929.9, recorded a low of Rs 2,850.

Gland Pharma Share Price Today opened at Rs 2,905.10, moved between Rs 2,850 and Rs 2,929.90, and was last traded at Rs 2,929.90. The stock added Rs 64.75 over the previous close of Rs 2,865.15, marking a 2.26% share price rise. Turnover stood at Rs 2.19 crore, which is useful for context on participation in the move. For readers searching Gland Pharma Stock News or Gland Pharma Share Price Update, the verified market picture is straightforward: the stock is rising today, it is near the day’s high, and the event is relevant because it reflects fresh price discovery in a large healthcare name. The latest Univest figures confirm the move, but they do not establish a company-specific catalyst.

Gland Pharma Ltd. (GLAND) Fundamental Analysis

Gland Pharma Ltd. (GLAND) fundamental metrics show P/E 41.87x, P/B 4.45x, ROE 10.56%, ROCE 14.96%. These figures provide context only and are not a buy or sell signal.

Gland Pharma Ltd. has a market capitalisation of Rs 47318.21 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 41.87x, P/B at 4.45x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 10.56% and ROCE of 14.96%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 68.43, book value per share of Rs 644.34, dividend yield of 0.7%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.97x, median ROE of 11.79%, median ROCE of 13.63%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Gland Pharma Ltd. (GLAND) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Gland Pharma Ltd. (GLAND) has a P/E ratio of 41.87x, which is above the benchmark median of 31.97x, a difference of +30.97%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Gland Pharma Ltd. (GLAND) has a ROE of 10.56%, which is below the benchmark median of 11.79%, a difference of -10.43%. Gland Pharma Ltd. (GLAND) has a ROCE of 14.96%, which is above the benchmark median of 13.63%, a difference of +9.76%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Gland Pharma Ltd. (GLAND) has a P/E ratio of 41.87x compared with the displayed peer median of 38.34x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 10.56% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 14.96% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Gland Pharma Ltd. (GLAND) has a market capitalisation of Rs 47,318.21 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Why Investors Are Watching Gland Pharma

• Gland Pharma Share Price is up 2.26% today, making it a clear stock in focus in Stocks in News and Market Movers.
• The stock is trading near the day’s high, which keeps Gland Pharma Share Price Today prominent for price action watchers.
• P/E of 41.87 and P/B of 4.45 place the stock above the industry median, so valuation remains central to Gland Pharma Fundamental Analysis.
• ROCE of 14.96 is above the industry median, which adds a useful profitability reference for Gland Pharma Stock News readers.
• The healthcare and pharmaceuticals backdrop keeps Gland Pharma Share Price relevant for investors following Indian Stock Market and NSE News.

About Gland Pharma

Gland Pharma Ltd. operates in the Pharmaceuticals & Drugs industry under the Healthcare sector. The company is best known as a pharmaceutical business with a market presence that is large enough to be followed closely in Gland Pharma Share Price news and broader Gland Pharma Stock Analysis. Its business model is associated with pharmaceutical products and industry participation that places it alongside other listed healthcare companies on the NSE and BSE. With a market capitalisation of Rs 47,318.21 crore, the company is materially larger than the industry median and remains a notable name in the segment. Investors tracking Gland Pharma Share Price Today generally compare its valuation, earnings and capital efficiency metrics with other pharma companies to understand how the market is pricing the business within the sector.

Frequently Asked Questions

Why is Gland Pharma Share Price rising today?

Ans. Gland Pharma Share Price is up 2.26% today to Rs 2,929.90. The latest Univest figures confirm the price event, but they do not establish a company-specific catalyst behind the move.

What is the current Gland Pharma Share Price Today?

Ans. Gland Pharma Share Price Today is Rs 2,929.90. It is trading above the previous close of Rs 2,865.15, which means the stock is showing a positive same-day gain.

How much did Gland Pharma stock gain today?

Ans. Gland Pharma stock gained Rs 64.75 today, which works out to a 2.26% rise. That move came after an open of Rs 2,905.10 and a day’s low of Rs 2,850.

What does Gland Pharma market cap indicate?

Ans. Gland Pharma market cap is Rs 47,318.21 crore. Market capitalisation reflects company size in the listed universe and helps investors compare Gland Pharma with larger and smaller pharma peers.

How does Gland Pharma valuation compare with the industry?

Ans. Gland Pharma’s P/E of 41.87 is above the industry median of 31.97 and below the average of 48.60. Its P/B of 4.45 is also above the median, keeping valuation in focus.

What do Gland Pharma EPS and book value show?

Ans. Gland Pharma EPS is 68.43 and book value is Rs 644.34. EPS shows earnings attributable to each share, while book value indicates the accounting net worth supporting each share.

How strong are Gland Pharma profitability ratios?

Ans. Gland Pharma reports ROE of 10.56 and ROCE of 14.96. ROE is slightly below the industry median, while ROCE is above both the industry median and average, which adds useful context.

How does Gland Pharma compare with pharma peers?

Ans. Gland Pharma’s P/E is higher than Zydus Lifesciences and Cipla, but lower than Divi’s Laboratories and Torrent Pharmaceuticals. Its market cap is also below the larger peer names in the group.

Track Gland Pharma Share Price on Univest

Use Gland Pharma Ltd. (GLAND) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Investors can track Gland Pharma Share Price on Univest for live share price updates, valuation ratios, company fundamentals, sector context and market insights. Univest also helps readers monitor Gland Pharma Share Price Live alongside key company metrics, so the latest stock news can be read with a broader research lens.